Individual sensitivity of ovarian ascitic cancer to thiophosphamide
Karuzina, N.P.; Shuvaeva, N.I.; Klimanova, Z.F.; Antoshechkina, E.T.
Voprosy Onkologii 20(8): 40-45
1974
ISSN/ISBN: 0507-3758 PMID: 4215221 Document Number: 78858
Document emailed within 1 workday
Related Documents
Kushlinskiĭ, N.E.; Podistov, I.I.; Laktionov, K.P.; Karseladze, A.I.; Babkina, I.V.; Kerimova, G.I. 1997: Prostaglandins e in the primary tumor, metastases, and ascitic fluid of patients with ovarian cancer Biulleten' Eksperimental'noi Biologii i Meditsiny 123(1): 83-86Mills, G.B.; May, C.; McGill, M.; Roifman, C.M.; Mellors, A. 1988: A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action Cancer Research 48(5): 1066-1071
Yin, D.; Zhang, X.; Feng, Y. 1996: Effects of recombinant human tumor necrosis factor on the development of ascitic tumor and expression of c-erbB2 in the nude mouse models of ovarian cancer Zhonghua Fu Chan Ke Za Zhi 31(5): 291-292
Gitel'man, A.K.; Martynenko, V.B.; Molibog, E.V.; Vorkunova, N.K.; Bukrinskaia, A.G. 1976: Abortive influenza virus infection in Ehrlich ascitic cancer cells. Further studies of the properties of ascitic virus Voprosy Virusologii 6: 713-721
Klotz, R.; Zeimet, A.G.; Reimer, D.; Müller-Holzner, E.; Chamson, M.; Marth, C. 2008: Activated p38-MAPK and gemcitabine sensitivity in recurrent ovarian cancer Anticancer Research 28(5b): 2975-2980
Fukuyama, A.; Yokoyama, Y.; Wada, J.; Hashimoto, T.; Oda, T.; Sato, S.; Mizunuma, H. 2009: Two cases of ovarian cancer at an early stage incidentally detected using transvaginal ultrasonography in screening: importance of interval for ovarian cancer screening and selection of population with a high risk of ovarian cancer European Journal of Gynaecological Oncology 30(2): 208-210
Yoshino, I.; Peoples, G.E.; Goedegebuure, P.S.; Maziarz, R.; Eberlein, T.J. 1994: Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer Journal of Immunology 152(5): 2393-2400
Li, Q.; Gao, J.-F.; Qi, B.-L. 2017: PDCD1 strengthens the sensitivity of ovarian cancer to cisplatin chemotherapy by promoting apoptosis Journal of Buon: Official Journal of the Balkan Union of Oncology 22(3): 746-756
Hartge, P.; Hayes, R.; Reding, D.; Sherman, M.E.; Prorok, P.; Schiffman, M.; Buys, S. 2000: Complex ovarian cysts in postmenopausal women are not associated with ovarian cancer risk factors: preliminary data from the prostate, lung, colon, and ovarian cancer screening trial American Journal of Obstetrics and Gynecology 183(5): 1232-1237
Sánchez-Lombraña, J.L.; De la Vega, J.; Fernández, E.; Pérez, R.; Linares, A.; Rodríguez, M.; Rodrígo, L. 1995: Characteristics of ascitic fluid in ovarian carcinomatosis Revista Espanola de Enfermedades Digestivas: Organo Oficial de la Sociedad Espanola de Patologia Digestiva 87(2): 127-138
Sawada, M.; Ozaki, M.; Hongo, J.; Hirota, Y.; Inagaki, M. 1987: Assessment of the establishing individual protocol for effective chemotherapy of ovarian cancer--fundamental research using human tumor-nude mouse system Nihon Sanka Fujinka Gakkai Zasshi 39(10): 1776-1783
Wang, G.; Shang, H-ling.; Xie, Y.; Xiao, P.; Li, X-jie.; Lin, T-cheng.; Li, G-yi. 2005: Effects of mifepristone on the proliferation, apoptosis and cis-diamminedichloroplatinum sensitivity of cultured chemoresistant human ovarian cancer cells Chinese Medical Journal 118(4): 333-336
Tropé, C.; Sigurdsson, K. 1982: Use of tissue culture in predictive testing of drug sensitivity in human ovarian cancer. Correlation between in vitro results and the response in vivo Neoplasma 29(3): 309-314
Shen, M.; Feng, Y.; Zhou, X. 1999: Effect of liposome-C-erbB2 antisense oligodeoxynucleotides on the growth and the chemotherapeutic drug sensitivity of human ovarian cancer transplanted in the omentum of nude mice Zhonghua Fu Chan Ke Za Zhi 34(2): 110-112
Kudoh, K.; Kita, T.; Hirata, J.; Ishii, K.; Hiramatsu, H.; Kikuchi, Y.; Nagata, I. 1994: Potentiation of cisplatin sensitivity of cisplatin-resistant human ovarian cancer cell lines by L-buthionine-S,R-sulfoximine Nihon Sanka Fujinka Gakkai Zasshi 46(6): 525-532
Yu, Y.; Zhang, X.; Tian, H.; Zhang, Z.; Tian, Y. 2018: Knockdown of long non-coding RNA HOTAIR increases cisplatin sensitivity in ovarian cancer by inhibiting cisplatin-induced autophagy Journal of BUON: Official Journal of the Balkan Union of Oncology 23(5): 1396-1401
Suzuki, M.; Sekiguchi, I.; Tamada, T.; Sakurabayashi, I.; Kawai, T. 1985: Clinical evaluation of a cancer antigen CA125 associated with ovarian cancer. (III) Serum CA125 levels in patients with ovarian cancer and other gynecological tumors Rinsho Byori. Japanese Journal of Clinical Pathology 33(2): 173-177
Rose, P.G.; Hunter, R.E. 1994: Advanced ovarian cancer in a woman with a family history of ovarian cancer, discovered at referral for prophylactic oophorectomy. A case report Journal of Reproductive Medicine 39(11): 908-910
Tanaka, K. 1989: Ovarian cancer--assessment of methods for cytogenetic analysis and chromosome aberrations found in ovarian cancer Rinsho Byori. Japanese Journal of Clinical Pathology Spec no 80: 268-280
Kudriashov, O.I.; Zateĭshchikov, D.A.; Sidorenko, B.A. 2005: Genetic basis of individual sensitivity to antiplatelet drugs Kardiologiia 45(9): 85-89